GlassScriptPhysician profile
Jack C Lunderman
NPI 1871694679
$7,905.52
in general payments reported to CMS, 2019-2025
27 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $563 · 2021: $912 · 2022: $1,130 · 2023: $1,375 · 2024: $1,638 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,092 · Education: $93.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,091.65 |
| Education | $93.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.96 | 2021-2025 | |
| Alkermes, INC. | $823.15 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $817.15 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $728.16 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $599.35 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $576.62 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $502.12 | 2019-2022 | |
| Lundbeck LLC | $422.45 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $383.23 | 2019-2025 | Trintellix |
| Allergan, INC. | $380.61 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $371.70 | 2019-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $338.39 | 2022-2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $185.11 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $127.00 | 2023-2025 | Xelstrym |
| Neurocrine Biosciences, INC. | $94.35 | 2022-2025 | Ingrezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $87.51 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $85.31 | 2019-2023 | Jornay Pm |
| Indivior INC. | $57.91 | 2019-2021 | |
| Biogen, INC. | $55.75 | 2024-2025 | Zurzuvae |
| Bausch Health US, LLC | $54.75 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $45.42 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $35.94 | 2022-2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $28.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $26.28 | 2019-2022 | |
| Corium, LLC | $20.04 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $19.74 | 2025 | Cobenfy |
| Almatica Pharma LLC | $14.89 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Lunderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.